apz2
Cell therapyexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started Aug 1, 2016 (NCT02742844)
Timeline
Indications
Mechanism of action
- Unspecified targetTissue restoration
tissue restoration
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- apz2
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05838092 | Phase 3 | Oct 18, 2023 | Rheacell GmbH & Co. KG |
| NCT05464381 | Phase 3 | Dec 31, 2022 | Rheacell GmbH & Co. KG |
| NCT02742844 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2016 | FGK Clinical Research GmbH, Granzer Regulatory Consulting & Services, Rheacell GmbH & Co. KG, TICEBA GmbH |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Rheacell GmbH & Co. KG | For profit | 3 | 3 | 2 | 2016 |
| FGK Clinical Research GmbH | For profit | 1 | 0 | 1 | 2016 |
| Granzer Regulatory Consulting & Services | For profit | 1 | 0 | 1 | 2016 |
| TICEBA GmbH | For profit | 1 | 0 | 1 | 2016 |
4 organizations
Page 1 / 1